Solvay Pharmaceuticals' Creon (pancrealipase delayed-release) has received US FDA approval for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.
Creon is the first pancreatic enzyme product (PEP) approved under an FDA initiative aimed at getting unapproved PEPs off the market. The approval came one year before an agency-imposed deadline...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?